Elipse Gastric Balloon Weight Loss Program Expands in Asia

Rapid Organic Growth in Europe, Middle East, and Latin America Sets the Stage for Further Global Expansion Company Names John Liljequist as the Director of Sales for Asia Pacific

Elipse Gastric Balloon Weight Loss Program Expands in Asia was reported today by Allurion Technologies.

Elipse Gastric Balloon Weight Loss Program is available in Hong Kong, Malaysia, and Singapore. Building upon its success in Europe, Middle East, and Latin America, the company’s entry into Asia could impact the lives of over 1 billion people who are overweight or obese in a region that historically has had limited access to non-invasive weight loss treatments.1

“With the launch of our weight loss program in Asia, our company enters its next phase of rapid expansion,” said Allurion co-founder and Chief Executive Officer, Shantanu Gaur, M.D. “Obesity has been on the rise in Asia for decades, but truly frictionless treatment options have been absent. We intend to change that.”

Allurion has already treated over 25,000 individuals in over 30 countries around the world with its 360-degree Allurion weight loss program. According to a study released by the Asian Development Bank Institute, over 40% of adults in Asia are overweight or obese, an increase of close to 20% in just the past 20 years.

“The arrival of the Elipse Balloon in Gleneagles Hospital Penang was a historical moment for all of us involved,” said Dr. Kirubakaran Malapan of Gleneagles Hospital Penang. “I am very confident that this will be an appealing treatment option in our fight against obesity.”

Allurion has also announced the addition of John Liljequist as the Director of Asia Pacific Sales. Mr. Liljequist has over 18 years of commercial medical device experience in the Asia Pacific region. Most recently he served as Senior Commercial Director at Establishment Labs and was responsible for driving sales, strategy and commercial activities across Japan, Korea, Hong Kong, Australia, and China. Prior to Establishment Labs, Mr. Liljequist managed the breast implant franchise at Allergan and was the integration lead for Coolsculpting® across APAC, India, the Middle East, and Africa.

“I am delighted to have John join the Allurion commercial team,” said Benoit Chardon, Allurion Executive Vice President of Global Commercial. “He is a joining at a time of substantial growth and will have an opportunity to deploy his talent, experience, and passion in one of the fastest-growing weight loss markets in the world.”


References

1 https://www.adb.org/sites/default/files/publication/320411/adbi-wp743.pdf

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”